IL-33 Polyclonal Antibody, PeproTech®, Invitrogen™

Description

• AA Sequence of recombinant protein: SITGISPITE YLASLSTYND QSITFALEDE SYEIYVEDLK KDEKKDKVLL SYYESQHPSN ESGDGVDGKM LMVTLSPTKD FWLHANNKEH SVELHKCEKP LPDQAFFVLH NMHSNCVSFE CKTDPGVFIG VKDNHLALIK VDSSENLCTE NILFKLSET
• Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human IL-33
• Anti-Human IL-33-specific antibody was purified by affinity chromatography employing an immobilized Human IL-33 matrix
• Sandwich ELISA: To detect Human IL-33 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required
• This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human IL-33 (500-P261Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human IL-33
• Western Blot: To detect Human IL-33 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL
• Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human IL-33 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions
• IL-33 (Interleukin-33) is a 270 amino acid, highly divergent protein belonging to the IL-1 family with an IL-1-like C-terminal domain
• IL-33 is a dual function protein that may function both as a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties
• IL-33 binds to and signals through IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6
• IL-33 activates NF-kappaB and MAP kinases, and drives production of TH2-associated cytokines from in vitro polarized TH2 cells
• In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs
• IL-33 is proteolytically converted to a mature form by CASP1 and is highly expressed in high endothelial venules found in tonsils, Peyer's patches and mesenteric lymph nodes and is almost undetectable in placenta
• Prolonged IL-33 treatment of mice led to the development of eosinophilia, splenomegaly, and severe pathological changes in mucosal organs such as lungs, esophagus and small intestine
• Recent experiments have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties
• Despite its predicted molecular weight, IL-33 will often run at higher molecular weight in SDS-PAGE
• Studies have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine, and an intracellular nuclear factor with transcriptional regulatory properties.